New pill HRS-5041 tested in men with Tough-to-Treat prostate cancer
NCT ID NCT06830850
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests an experimental oral drug called HRS-5041 in 25 men with metastatic castration-resistant prostate cancer, a form of prostate cancer that has spread and no longer responds to standard hormone therapy. The main goal is to check the drug's safety and how the body processes it. Participants take the drug daily in 28-day cycles, and researchers will monitor side effects, vital signs, and lab results.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HRS-5041 (oral tablet)
What this could lead to
If it works, this could point toward a new treatment option for men with advanced prostate cancer that has stopped responding to standard hormone therapy.
What could go wrong
This is a very early Phase 1 trial with only 25 participants, so the main goal is safety, not proof of effectiveness. The drug may not work or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Research SA
RECRUITINGAdelaide, South Australia, Australia
Contact
Contact
-
Eastern Health (Box Hill Hospital)
RECRUITINGMelbourne, Australia
Contact
-
GenesisCare North Shore (Oncology)
RECRUITINGSydney, New South Wales, Australia
Contact
-
Icon Cancer Centre South Brisbane
RECRUITINGBrisbane, Australia
Contact
-
Illawarra Shoalhaven Local Health District (Wollongong Hospital)
RECRUITINGWollongong, Australia
Contact
-
John Flynn Private Hospital
RECRUITINGBrisbane, Australia
Contact
-
Linear Clinical Research Ltd
RECRUITINGPerth, Australia
Contact
-
MUPharm Pty Limited trading as Macquarie University Hospital Pharmacy
RECRUITINGSydney, Australia
Contact
Contact
-
Macquarie University
RECRUITINGSydney, Australia
Contact
-
Southern Oncology Clinical Research Unit
RECRUITINGAdelaide, South Australia, Australia
Contact
-
Sydney Adventist Hospital
RECRUITINGSydney, New South Wales, Australia
Contact